Korlym
Drug
Corcept Therapeutics
Total Payments
$17.3M
Transactions
111,086
Doctors
20,930
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.9M | 34,475 | 11,432 |
| 2023 | $2.8M | 20,708 | 6,633 |
| 2022 | $1.6M | 13,941 | 4,206 |
| 2021 | $1.5M | 13,659 | 4,121 |
| 2020 | $851,124 | 6,502 | 1,959 |
| 2019 | $1.4M | 8,450 | 2,459 |
| 2018 | $3.5M | 7,032 | 2,279 |
| 2017 | $1.9M | 6,319 | 2,138 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.7M | 2,168 | 27.1% |
| Unspecified | $4.2M | 451 | 24.2% |
| Food and Beverage | $2.6M | 102,291 | 15.2% |
| Consulting Fee | $2.6M | 1,123 | 14.9% |
| Travel and Lodging | $1.5M | 3,825 | 8.8% |
| Honoraria | $1.4M | 560 | 8.2% |
| Grant | $152,052 | 21 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $77,030 | 35 | 0.4% |
| Education | $13,491 | 605 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,930 | 6 | 0.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,500 | 1 | 0.0% |
Payments by Type
General
$13.1M
110,635 transactions
Research
$4.2M
451 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study 550 | Corcept Therapeutics | $2.5M | 0 |
| CORT125281-601 | Corcept Therapeutics | $397,744 | 0 |
| Study 500 | Corcept Therapeutics | $224,230 | 0 |
| Study 451 | Corcept Therapeutics | $197,382 | 0 |
| CORT125134-552 | Corcept Therapeutics | $180,962 | 0 |
| Study 700 | Corcept Therapeutics | $174,731 | 0 |
| C1073-500 Phase 1 Study of Mifepristone in Combination with Eribulin in Patients with Locally AdvancedMetastatic Breast Cancer or Other Specified Solid Tumors, with a Dose Expansion Cohort in Patients with Triple Negative Breast Cancer | Corcept Therapeutics | $130,132 | 0 |
| CORT125134-451 Cushing's Syndrome | Corcept Therapeutics | $84,948 | 0 |
| FKBP5-700 | Corcept Therapeutics | $73,069 | 0 |
| Study 601 | Corcept Therapeutics | $63,315 | 0 |
| CATALYST | Corcept Therapeutics | $33,568 | 22 |
| C1073-38 | Corcept Therapeutics | $26,769 | 0 |
| CORT125134-550 | Corcept Therapeutics | $26,347 | 0 |
| CORT 125134-451 | Corcept Therapeutics | $21,623 | 0 |
| C1073-500 | Corcept Therapeutics | $13,964 | 0 |
| Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome | Corcept Therapeutics | $12,520 | 0 |
| CORT FKBP5-700 | Corcept Therapeutics | $11,277 | 0 |
| STOMP-CSC | Corcept Therapeutics | $7,500 | 0 |
| Study FKBP5-700 | Corcept Therapeutics | $6,293 | 0 |
| Study to test ability of drugs to inhibit cancer cell lines | Corcept Therapeutics | $5,000 | 0 |
Top Doctors Receiving Payments for Korlym — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Endocrinology, Diabetes & Metabolism | San Antonio, TX | $120,472 | 50 |
| , MD | Endocrinology, Diabetes & Metabolism | Storrs, CT | $117,708 | 144 |
| , MD | Nephrology | Lufkin, TX | $114,104 | 135 |
| , D.O | Endocrinology, Diabetes & Metabolism | Tomball, TX | $108,166 | 169 |
| , MD PHD | Endocrinology, Diabetes & Metabolism | Easton, CT | $100,265 | 200 |
| , MD | Internal Medicine | San Carlos, CA | $96,558 | 225 |
| , D.O | Family Medicine | Leeds, AL | $96,166 | 168 |
| , MD | Endocrinology, Diabetes & Metabolism | Nashville, TN | $95,136 | 68 |
| , M.D | Endocrinology, Diabetes & Metabolism | Nashville, TN | $91,301 | 186 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $90,749 | 105 |
| , MD | Endocrinology, Diabetes & Metabolism | Miami, FL | $87,925 | 156 |
| , MD | Endocrinology, Diabetes & Metabolism | Terre Haute, IN | $87,741 | 190 |
| , MD | Endocrinology, Diabetes & Metabolism | Ann Arbor, MI | $84,575 | 99 |
| , M.D | Endocrinology, Diabetes & Metabolism | Laguna Hills, CA | $84,112 | 133 |
| , MD | Endocrinology, Diabetes & Metabolism | Edmond, OK | $81,900 | 206 |
| , M.D | Internal Medicine | Algonquin, IL | $78,600 | 177 |
| , M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $77,479 | 91 |
| , DO | Endocrinology, Diabetes & Metabolism | Corinth, MS | $77,054 | 140 |
| , MBCHB, MD, FRCP(UK) | Endocrinology, Diabetes & Metabolism | Portland, OR | $73,349 | 130 |
| , M.D | Internal Medicine | San Antonio, TX | $72,110 | 164 |
| , MD | Endocrinology, Diabetes & Metabolism | San Antonio, TX | $68,730 | 139 |
| , M.D | Internal Medicine | Humboldt, IA | $68,645 | 171 |
| , M.D | Endocrinology, Diabetes & Metabolism | Fall River, MA | $63,827 | 112 |
| , PA | Physician Assistant | Milwaukee, WI | $62,878 | 86 |
| , M.D | Endocrinology, Diabetes & Metabolism | Wilmington, NC | $59,348 | 127 |
Ad
Manufacturing Companies
- Corcept Therapeutics $17.3M
Product Information
- Type Drug
- Total Payments $17.3M
- Total Doctors 20,930
- Transactions 111,086
About Korlym
Korlym is a drug associated with $17.3M in payments to 20,930 healthcare providers, recorded across 111,086 transactions in the CMS Open Payments database. The primary manufacturer is Corcept Therapeutics.
Payment data is available from 2017 to 2024. In 2024, $3.9M was paid across 34,475 transactions to 11,432 doctors.
The most common payment nature for Korlym is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($4.7M, 27.1% of total).
Korlym is associated with 20 research studies, including "Study 550" ($2.5M).